Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region

Description

List of Tables

The gout therapeutics market size is expected to reach USD 6.15 billion by 2034, according to a new study by Polaris Market Research. The report "Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gout therapeutics market addresses the clinical need for managing hyperuricemia and recurrent inflammatory arthritis resulting from monosodium urate crystal deposition. Treatment involves both acute management and long-term urate-lowering strategies to prevent flares and joint damage. Market growth is being driven by increasing disease burden, driven in part by rising obesity rates, sedentary lifestyles, and associated metabolic conditions such as hypertension and chronic kidney disease. Accelerated diagnostic timelines and increased awareness among both patients and healthcare providers are leading to earlier treatment initiation, expanding the patient pool for therapeutic intervention.

Industry players are investing in targeted therapies that minimize adverse events while offering improved efficacy, particularly for patients unresponsive to conventional treatment. Trends such as biologic innovation, precision medicine approaches, and focus on comorbidity-friendly formulations are gaining traction. Opportunities are emerging through pipeline expansion in urate transport modulation and interleukin-1B inhibition. Regulatory bodies are providing fast-track pathways for breakthrough therapies, encouraging R&D investments. Companies are forming strategic collaborations to co-develop and commercialize novel agents, leveraging shared expertise and regional market access. The market is also witnessing a shift toward patient-centric care models, incorporating treatment adherence tools and digital health integration.

Gout Therapeutics Market Report Highlights

By drug class, the NSAIDs segment dominated the market with ~43% of the revenue share in 2024 due to their rapid action in reducing inflammation and pain associated with acute gout flares.

Based on disease condition, the chronic gout segment held the largest revenue share in 2024 due to growing demand for long-term management therapies.

North America accounted for ~50% of the gout therapeutics market revenue share in 2024 due to strong healthcare infrastructure, early diagnosis, and widespread access to specialized rheumatology care.

The market in Asia Pacific is expected to register the highest CAGR from 2025 to 2034 due to growing awareness about gout treatment, improving healthcare access, and the rising prevalence of lifestyle diseases contributing to hyperuricemia.

A few global key players include Arrowhead Pharmaceuticals, Inc.; AstraZeneca; GSK plc.; Eisai Co., Ltd.; Merck & Co., Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teijin Pharma Ltd.; and Zydus Group.

Polaris Market Research has segmented the market report on the basis of disease condition, drug class, distribution channel, and region:

By Disease Condition Outlook (Revenue, USD Billion, 2020-2034)

Acute Gout

Chronic Gout

By Drug Class Outlook (Revenue, USD Billion, 2020-2034)

NSAIDs

Corticosteroids

Colchicine

Urate-Lowering Agents

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Product Code: PM1611

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Gout Therapeutics Market Insights

4.1. Gout Therapeutics Market - Market Snapshot
4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Prevalence of Gout and Lifestyle Disorders
  - 4.2.1.2. Increased Geriatric Population Base
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High cost of advanced therapies and limited reimbursement in emerging markets.
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Gout Therapeutics Market Trends
4.6. Value Chain Analysis

5. Global Gout Therapeutics Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
5.3. NSAIDs
- 5.3.1. Global Gout Therapeutics Market, by NSAIDs, by Region, 2020-2034 (USD Billion)
5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2020-2034 (USD Billion)
5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2020-2034 (USD Billion)
5.6. Urate-Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate-Lowering Agents, by Region, 2020-2034 (USD Billion)
5.7. Others
- 5.7.1. Global Gout Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Gout Therapeutics Market, by Disease Condition

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
6.3. Acute Gout
- 6.3.1. Global Gout Therapeutics Market, by Acute Gout, by Region, 2020-2034 (USD Billion)
6.4. Chronic Gout
- 6.4.1. Global Gout Therapeutics Market, by Chronic Gout, by Region, 2020-2034 (USD Billion)

7. Global Gout Therapeutics Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacy
- 7.3.1. Global Gout Therapeutics Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
7.4. Retail Pharmacy
- 7.4.1. Global Gout Therapeutics Market, by Retail Pharmacy, by Region, 2020-2034 (USD Billion)
7.5. Online Pharmacy
- 7.5.1. Global Gout Therapeutics Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)

8. Global Gout Therapeutics Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Gout Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Gout Therapeutics Market - North America
- 8.3.1. North America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.3.2. North America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.3.3. North America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.4. Gout Therapeutics Market - U.S.
  - 8.3.4.1. U.S.: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.5. Gout Therapeutics Market - Canada
  - 8.3.5.1. Canada: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
8.4. Gout Therapeutics Market - Europe
- 8.4.1. Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.2. Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.3. Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.4. Gout Therapeutics Market - UK
  - 8.4.4.1. UK: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.5. Gout Therapeutics Market - France
  - 8.4.5.1. France: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.6. Gout Therapeutics Market - Germany
  - 8.4.6.1. Germany: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.7. Gout Therapeutics Market - Italy
  - 8.4.7.1. Italy: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.8. Gout Therapeutics Market - Spain
  - 8.4.8.1. Spain: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.9. Gout Therapeutics Market - Netherlands
  - 8.4.9.1. Netherlands: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.10. Gout Therapeutics Market - Russia
  - 8.4.10.1. Russia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.11. Gout Therapeutics Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
8.5. Gout Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.4. Gout Therapeutics Market - China
  - 8.5.4.1. China: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.5. Gout Therapeutics Market - India
  - 8.5.5.1. India: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.6. Gout Therapeutics Market - Malaysia
  - 8.5.6.1. Malaysia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.7. Gout Therapeutics Market - Japan
  - 8.5.7.1. Japan: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.8. Gout Therapeutics Market - Indonesia
  - 8.5.8.1. Indonesia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.9. Gout Therapeutics Market - South Korea
  - 8.5.9.1. South Korea: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.10. Gout Therapeutics Market - Australia
  - 8.5.10.1. Australia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.11. Gout Therapeutics Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
8.6. Gout Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.4. Gout Therapeutics Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.5. Gout Therapeutics Market - UAE
  - 8.6.5.1. UAE: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.6. Gout Therapeutics Market - Israel
  - 8.6.6.1. Israel: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.7. Gout Therapeutics Market - South Africa
  - 8.6.7.1. South Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.8. Gout Therapeutics Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
8.7. Gout Therapeutics Market - Latin America
- 8.7.1. Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.4. Gout Therapeutics Market - Mexico
  - 8.7.4.1. Mexico: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.5. Gout Therapeutics Market - Brazil
  - 8.7.5.1. Brazil: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.6. Gout Therapeutics Market - Argentina
  - 8.7.6.1. Argentina: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.7. Gout Therapeutics Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Arrowhead Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. AstraZeneca
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Eisai Co., Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. GSK plc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Merck & Co., Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Novartis AG
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Takeda Pharmaceutical Company Limited
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Teijin Pharma Ltd.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Zydus Group
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Regeneron Pharmaceuticals Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development